Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform

Vaccine

Volumn 30, Issue 50, 2012, Pages 7265-7270

  Gabitzsch, Elizabeth S ^a   Balint Junior, Joseph P ^a   Xu, Younong ^a   Balcaitis, Stephanie ^a   Sanders Beer, Brigitte ^b   Karl, Julie ^c   Weinhold, Kent J ^d   Paessler, Slobodan ^e   Jones, Frank R ^a  

^a Etubics Corporation   (United States)

^b BIOQUAL INC   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d DUKE UNIVERSITY   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Ad5 E1 , E2b ; Ad5 immunity; Adenovirus vector; HIV vaccine; SIVmac239

Indexed keywords

ADENOVIRUS VECTOR; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FOLLOW UP; GENE DELIVERY SYSTEM; IMMUNIZATION; INFECTION CONTROL; INFLUENZA A (H1N1); NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DRUG CARRIERS; GENETIC VECTORS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MACACA MULATTA; MALE; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 84869876506     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.058     Document Type: Article

References (35)

1. Tatsis N., Lasaro M.O., Lin S.W., Haut L.H., Xiang Z.Q., Zhou D., et al. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 2009, 182:6587-6599.
2. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007, 81:6594-6604.
3. Cantanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase I safety and immnogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194:1638-1649.
4. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46:1769-1781.
5. Barouch D.H., Kik S.V., Weverling G.J., Dilan R., King S.L., Maxfield L.F., et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, 29:5203-5209.
6. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006, 12:1596-1599.
7. Hutnick N.A., Carnathan D., Demers K., Makedonas G., Ertl H., Betts M.R. Adenovirus-specific human T cells are pervasive, polyfuntional, and cross reactive. Vaccine 2010, 28:1932-1941.
8. Frahm N., DeCamp A.C., Friedrich D.P., Carter D.K., Defawe O.D., Kublin J.G., et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012, 122:359-367.
9. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998, 72:926-933.
10. Gabitzsch E.S., Xu Y., Yoshida L., Balint J., Gayle R.B., Amalfitanto A., et al. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 2009, 122:44-51.
11. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Amalfitano A., Jones F.R. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009, 27:6394-6398.
12. Gabitzsch E.S., Xu Y., Balint J.P., Hartman Z.C., Lyerly H.K., Jones F.R. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral [E1-, E2b-]-CEA. Cancer Immunol Immunother 2010, 59:1131-1135.
13. Gabitzsch E.S., Xu Y., Balcaitis S., Balint J.P., Jones F.R. An Ad5(E1-, E2b-)-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 2011, 18:326-335.
14. Gabitzsch E.S., Xu Y., Balcaitis S., Balint J.P., Induction Jones F.R. Comparison of SIV immunity in Ad5 Naïve and Ad5 Immune Non-human Primates using an Ad5[E1-, E2b-] based vaccine. Vaccine 2011, 29:8101-8107.
15. Osada T., Yang X.Y., Hartman Z.C., Glass O., Hodges B.L., Niedzwiecki D., et al. Optimization of vaccine responses with an E1, E2b, E3 deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009, 16:673-682.
16. Jones F.R., Gabitzsch E.S., Xu Y., Balint J.P., Borisevich V., Smith J., et al. Prevention of influenza virus shedding and protection from lethal H1 N1 challenge using a consensus 2009 H1 N1 HA and NA adenovirus vector vaccine. Vaccine 2011, 29:7020-7026.
17. Balint J.P., Jones F.R. Detection of elevated levels of antiidiotypic antibody levels in immune thrombocytopenic patients expressing antiplatelet antibody. Blood 1994, 84:664-665.
18. Lewis M.G., Norelli S., Collins M., Barreca M.L., Iraci N., Chirullo B., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010, 7:21.
19. Lagenaur L.A., Sanders-Beer B.E., Brichacek B., Pal R., Liu X., Liu Y., et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011, 6:648-657.
20. Wiseman R.W., Karl J.A., Bimber B.N., O'Leary C.E., Lank S.M., Tuscher J.J., et al. Major histocompatibility complex genotyping with massively parallel pyrosequencing. Nat Med 2009, 15:1322-1326.
21. Loffredo J.T., Maxwell J., Qi Y., Glidden C.E., Borchardt G.J., Soma T., et al. Mamu-B 08-positive macaques control simian immunodeficiency virus replication. J Virol 2007, 81:8827-8832.
22. Lewis M.G., Bellah S., McKinnon K., Yalley-Ogunro J., Zack P.M., Elkins W.R., et al. Titration and characterization of two Rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses 1994, 10:213-220.
23. Parham P. Putting a face to MHC restriction. J Immunol 2005, 174:3-5.
24. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Accessed at: ; May 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/.
25. Chen S., Chunhui L., Xiaoxiang W., Yaozheng L., Daishu H., Weizhong G., et al. Variability of bio-clinical parameters in Chinese-origin rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model. PLoS ONE 2011, 6:e23177.
26. Alpert M., Harvey J., Lauer W., Reeves R., Piatak M., Carville A., et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PloS Pathog 2012, 8:e1002890.
27. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
28. Campos S.K., Barry M.A. Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 2007, 7:189-204.
29. Tatsis N., Ertl H.C.J. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629.
30. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
31. Cheng C., Wang L., Gall J., Nason M., Schwartz R., McElrath J., et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS ONE 2012, 7(4):e33969.
32. Duerr A., Huang Y., Buchbinder S., Coombs R.W., Sanchez J., del Rio C., et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012, 206:258-266.
33. Lemckerk A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005, 79:9694-9701.
34. Koblin B.A., Mayer K.H., Noonan E., Wang C.Y., Marmor M., Sanxhez J. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 2012, 60:405-413.
35. Stephenson K.A., Hural J., Buchbinder S.P., Sinangil F., Barouch D.H. Preexisting adenovirus seropositivity is not associated with HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis 2012, 205:1806-1810.